Fishman Jay A Ltd. MI Has $2.78 Million Holdings in Danaher Co. (NYSE:DHR)

Share on StockTwits

Fishman Jay A Ltd. MI cut its holdings in shares of Danaher Co. (NYSE:DHR) by 2.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,246 shares of the conglomerate’s stock after selling 500 shares during the period. Fishman Jay A Ltd. MI’s holdings in Danaher were worth $2,780,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. Zevin Asset Management LLC raised its position in shares of Danaher by 1.2% in the 3rd quarter. Zevin Asset Management LLC now owns 67,015 shares of the conglomerate’s stock valued at $9,679,000 after acquiring an additional 768 shares during the period. Reilly Herbert Faulkner III raised its holdings in shares of Danaher by 1.1% during the 3rd quarter. Reilly Herbert Faulkner III now owns 48,323 shares of the conglomerate’s stock valued at $6,979,000 after buying an additional 516 shares in the last quarter. Private Ocean LLC purchased a new position in shares of Danaher during the 3rd quarter valued at about $39,000. Bingham Osborn & Scarborough LLC purchased a new position in shares of Danaher during the 3rd quarter valued at about $237,000. Finally, Bourgeon Capital Management LLC raised its holdings in shares of Danaher by 0.4% during the 3rd quarter. Bourgeon Capital Management LLC now owns 55,684 shares of the conglomerate’s stock valued at $8,042,000 after buying an additional 230 shares in the last quarter. Institutional investors own 78.30% of the company’s stock.

A number of brokerages recently weighed in on DHR. Piper Jaffray Companies raised their price objective on Danaher from $148.00 to $153.00 and gave the company a “neutral” rating in a report on Thursday, July 18th. Argus raised their price objective on Danaher to $165.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. ValuEngine cut Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Wolfe Research set a $154.00 price objective on Danaher and gave the company a “buy” rating in a report on Friday, October 25th. Finally, Needham & Company LLC decreased their price objective on Danaher from $155.00 to $152.00 and set a “buy” rating on the stock in a report on Monday, October 28th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $145.86.

In related news, Chairman Mitchell P. Rales purchased 2,500 shares of Danaher stock in a transaction that occurred on Friday, August 23rd. The shares were acquired at an average cost of $139.52 per share, for a total transaction of $348,800.00. Following the transaction, the chairman now directly owns 3,030,453 shares in the company, valued at $422,808,802.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.40% of the stock is owned by company insiders.

DHR traded up $0.73 on Friday, hitting $135.23. 1,633,369 shares of the company were exchanged, compared to its average volume of 2,487,994. The firm has a fifty day simple moving average of $139.07 and a two-hundred day simple moving average of $138.28. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.09 and a current ratio of 3.43. Danaher Co. has a 12 month low of $94.59 and a 12 month high of $147.33. The stock has a market capitalization of $95.87 billion, a PE ratio of 29.92, a price-to-earnings-growth ratio of 2.24 and a beta of 0.92.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Thursday, October 24th. The conglomerate reported $1.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.15 by $0.01. Danaher had a return on equity of 11.42% and a net margin of 12.13%. The business had revenue of $5.04 billion for the quarter, compared to analyst estimates of $5.02 billion. During the same period last year, the company earned $1.10 EPS. Danaher’s revenue for the quarter was up 3.8% compared to the same quarter last year. On average, equities analysts expect that Danaher Co. will post 4.76 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a dividend of $0.17 per share. The ex-dividend date was Thursday, September 26th. This represents a $0.68 annualized dividend and a yield of 0.50%. Danaher’s payout ratio is 15.04%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Featured Story: What are no-load funds?

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

EagleX Price Reaches $0.0003
EagleX Price Reaches $0.0003
Financial Analysis: CEMIG  & Biotricity
Financial Analysis: CEMIG & Biotricity
Analysts Expect West Pharmaceutical Services Inc.  to Post $0.72 Earnings Per Share
Analysts Expect West Pharmaceutical Services Inc. to Post $0.72 Earnings Per Share
Bank of America  Rating Reiterated by Morgan Stanley
Bank of America Rating Reiterated by Morgan Stanley
GDS  PT Raised to $62.00
GDS PT Raised to $62.00
K&S  Given a €12.70 Price Target by Independent Research Analysts
K&S Given a €12.70 Price Target by Independent Research Analysts


© 2006-2019 Ticker Report